The FY2023 (Dec) proxy of Coherus Oncology names 21 peer companies for pay. Among Coherus Oncology and these peers, CEO pay was 5th highest of 8 and total shareholder return was the lowest of 8.
5th highest of 8in Coherus Oncology and its pay peers, FY2023 (Dec) by CEO pay:
$3.1M$8.9M
8th highest of 8in Coherus Oncology and its pay peers, FY2023 (Dec) by total shareholder return:
-$82$185
Pay peer group, FY2023 (Dec) proxy
| PTC Therapeutics | ||
| Ironwood Pharmaceuticals | ||
| Pacira BioSciences | ||
| Mirum Pharmaceuticals | ||
| Agenus | ||
| Agios Pharmaceuticals | ||
| Nektar Therapeutics | ||
| Acadia Pharmaceuticals | Not disclosed | Not disclosed |
| Aerie Pharmaceuticals | Not disclosed | Not disclosed |
| Amicus Pharmaceuticals | Not disclosed | Not disclosed |
| Collegium Pharmaceuticals | Not disclosed | Not disclosed |
| Corcept Therapeutics | Not disclosed | Not disclosed |
| Deciphera Pharmaceuticals | Not disclosed | Not disclosed |
| Dynavax Technologies | Not disclosed | Not disclosed |
| Eagle Pharmaceuticals | Not disclosed | Not disclosed |
| Fibrogen | Not disclosed | Not disclosed |
| Heron Therapeutics | Not disclosed | Not disclosed |
| Intercept Pharmaceuticals | Not disclosed | Not disclosed |
| Karyopharm Therapeutics | Not disclosed | Not disclosed |
| Supemus Pharmaceuticals | Not disclosed | Not disclosed |
| Vanda Pharmaceuticals | Not disclosed | Not disclosed |
21 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.